Effect of Rifampin on the Pharmacokinetics of BAY73-4506

PHASE1CompletedINTERVENTIONAL
Enrollment

24

Participants

Timeline

Start Date

March 31, 2011

Primary Completion Date

June 30, 2011

Study Completion Date

June 30, 2011

Conditions
Neoplasms
Interventions
DRUG

Regorafenib (BAY73-4506) + rifampin

Drug: BAY73-4506 A single 160-mg dose of BAY73-4506 will be administered in the fasted state on Day 1 as four 40 mg tablets. Drug: BAY73-4506 and rifampin 600 mg once a day doses of rifampin will be orally administered after overnight fasting from Day 15 to Day 23. A single 160-mg dose of BAY73-4506 will be administered in the fasted state on Day 21 as four 40 mg tablets.

Trial Locations (1)

78744

Austin

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Bayer

INDUSTRY

NCT01322438 - Effect of Rifampin on the Pharmacokinetics of BAY73-4506 | Biotech Hunter | Biotech Hunter